480 related articles for article (PubMed ID: 16444869)
41. Endothelial dysfunction in patients with peripheral arterial disease and chronic hyperhomocysteinemia: potential role of ADMA.
Sydow K; Hornig B; Arakawa N; Bode-Böger SM; Tsikas D; Münzel T; Böger RH
Vasc Med; 2004 May; 9(2):93-101. PubMed ID: 15521698
[TBL] [Abstract][Full Text] [Related]
42. Arginine, arginine analogs and nitric oxide production in chronic kidney disease.
Baylis C
Nat Clin Pract Nephrol; 2006 Apr; 2(4):209-20. PubMed ID: 16932427
[TBL] [Abstract][Full Text] [Related]
43. Cytomegalovirus infection impairs the nitric oxide synthase pathway: role of asymmetric dimethylarginine in transplant arteriosclerosis.
Weis M; Kledal TN; Lin KY; Panchal SN; Gao SZ; Valantine HA; Mocarski ES; Cooke JP
Circulation; 2004 Feb; 109(4):500-5. PubMed ID: 14732750
[TBL] [Abstract][Full Text] [Related]
44. The DDAH/ADMA/NOS pathway.
Tran CT; Leiper JM; Vallance P
Atheroscler Suppl; 2003 Dec; 4(4):33-40. PubMed ID: 14664901
[TBL] [Abstract][Full Text] [Related]
45. Role of asymmetrical dimethylarginine in renal microvascular endothelial dysfunction in chronic renal failure with hypertension.
Okubo K; Hayashi K; Wakino S; Matsuda H; Kubota E; Honda M; Tokuyama H; Yamamoto T; Kajiya F; Saruta T
Hypertens Res; 2005 Feb; 28(2):181-9. PubMed ID: 16025746
[TBL] [Abstract][Full Text] [Related]
46. Gene transfer of dimethylarginine dimethylaminohydrolase-2 improves the impairments of DDAH/ADMA/NOS/NO pathway in endothelial cells induced by lysophosphatidylcholine.
Feng M; Liu L; Guo Z; Xiong Y
Eur J Pharmacol; 2008 Apr; 584(1):49-56. PubMed ID: 18342305
[TBL] [Abstract][Full Text] [Related]
47. The biochemistry, measurement and current clinical significance of asymmetric dimethylarginine.
Blackwell S
Ann Clin Biochem; 2010 Jan; 47(Pt 1):17-28. PubMed ID: 19940201
[TBL] [Abstract][Full Text] [Related]
48. Increased (E)-4-hydroxy-2-nonenal and asymmetric dimethylarginine concentrations and decreased nitric oxide concentrations in the plasma of patients with major depression.
Selley ML
J Affect Disord; 2004 Jun; 80(2-3):249-56. PubMed ID: 15207938
[TBL] [Abstract][Full Text] [Related]
49. [Asymmetric dimethylarginine--a novel cardiovascular risk factor].
Siroká R; Cibulka R; Rajdl D; Racek J
Vnitr Lek; 2006 Mar; 52(3):249-55. PubMed ID: 16722156
[TBL] [Abstract][Full Text] [Related]
50. The role of nitric oxide synthase inhibition by asymmetric dimethylarginine in the pathophysiology of preeclampsia.
Böger RH; Diemert A; Schwedhelm E; Lüneburg N; Maas R; Hecher K
Gynecol Obstet Invest; 2010; 69(1):1-13. PubMed ID: 19828999
[TBL] [Abstract][Full Text] [Related]
51. Asymmetric dimethylarginine (ADMA), symmetric dimethylarginine (SDMA) and homoarginine (hArg): the ADMA, SDMA and hArg paradoxes.
Tsikas D; Bollenbach A; Hanff E; Kayacelebi AA
Cardiovasc Diabetol; 2018 Jan; 17(1):1. PubMed ID: 29301528
[TBL] [Abstract][Full Text] [Related]
52. Role of asymmetric dimethylarginine in vascular injury in transgenic mice overexpressing dimethylarginie dimethylaminohydrolase 2.
Hasegawa K; Wakino S; Tatematsu S; Yoshioka K; Homma K; Sugano N; Kimoto M; Hayashi K; Itoh H
Circ Res; 2007 Jul; 101(2):e2-10. PubMed ID: 17601800
[TBL] [Abstract][Full Text] [Related]
53. Role of dimethylarginine dimethylaminohydrolases in the regulation of endothelial nitric oxide production.
Pope AJ; Karrupiah K; Kearns PN; Xia Y; Cardounel AJ
J Biol Chem; 2009 Dec; 284(51):35338-47. PubMed ID: 19820234
[TBL] [Abstract][Full Text] [Related]
54. Variance of DDAH/PRMT/ADMA pathway in atrial fibrillation dogs.
Liu H; Qu X; Liang Z; Chen W; Xia W; Song Y
Biochem Biophys Res Commun; 2008 Dec; 377(3):884-8. PubMed ID: 18951871
[TBL] [Abstract][Full Text] [Related]
55. Taurine protects against low-density lipoprotein-induced endothelial dysfunction by the DDAH/ADMA pathway.
Tan B; Jiang DJ; Huang H; Jia SJ; Jiang JL; Hu CP; Li YJ
Vascul Pharmacol; 2007 May; 46(5):338-45. PubMed ID: 17293168
[TBL] [Abstract][Full Text] [Related]
56. Human recombinant erythropoietin augments serum asymmetric dimethylarginine concentrations but does not compromise nitric oxide generation in mice.
Desai A; Zhao Y; Warren JS
Nephrol Dial Transplant; 2008 May; 23(5):1513-20. PubMed ID: 18204093
[TBL] [Abstract][Full Text] [Related]
57. The effect of nebivolol on asymmetric dimethylarginine system in spontaneously hypertension rats.
Wang Y; Zhang M; Liu Y; Liu Y; Chen M
Vascul Pharmacol; 2011; 54(1-2):36-43. PubMed ID: 21167314
[TBL] [Abstract][Full Text] [Related]
58. Dimethylarginine dimethylaminohydrolase regulation: a novel therapeutic target in cardiovascular disease.
Wadham C; Mangoni AA
Expert Opin Drug Metab Toxicol; 2009 Mar; 5(3):303-19. PubMed ID: 19331593
[TBL] [Abstract][Full Text] [Related]
59. Plasma concentration of asymmetric dimethylarginine, an endogenous inhibitor of nitric oxide synthase, is elevated in monkeys with hyperhomocyst(e)inemia or hypercholesterolemia.
Böger RH; Bode-Böger SM; Sydow K; Heistad DD; Lentz SR
Arterioscler Thromb Vasc Biol; 2000 Jun; 20(6):1557-64. PubMed ID: 10845872
[TBL] [Abstract][Full Text] [Related]
60. Homocysteine impairs the nitric oxide synthase pathway: role of asymmetric dimethylarginine.
Stühlinger MC; Tsao PS; Her JH; Kimoto M; Balint RF; Cooke JP
Circulation; 2001 Nov; 104(21):2569-75. PubMed ID: 11714652
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
